MENU
+Compare
CLLS
Stock ticker: NASDAQ
AS OF
Dec 18, 04:01 PM (EDT)
Price
$1.68
Change
-$0.03 (-1.75%)
Capitalization
168.21M

CLLS Cellectis SA Forecast, Technical & Fundamental Analysis

a genome engineering company of pre-engineered products for pharmaceutical industry, cell therapies, seed companies, and laboratory researchers

Industry Biotechnology
CLLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
a Summary for CLLS with price predictions
Dec 17, 2024

CLLS in upward trend: price may jump up because it broke its lower Bollinger Band on December 13, 2024

CLLS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 33 cases where CLLS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for CLLS's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CLLS advanced for three days, in of 248 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 124 cases where CLLS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 10, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on CLLS as a result. In of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for CLLS turned negative on December 10, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .

CLLS moved below its 50-day moving average on December 11, 2024 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CLLS crossed bearishly below the 50-day moving average on December 16, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLLS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.319) is normal, around the industry mean (14.664). P/E Ratio (0.000) is within average values for comparable stocks, (87.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.783). CLLS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (4.801) is also within normal values, averaging (260.687).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CLLS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
CLLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

CLLS is expected to report earnings to fall 19.57% to -18 cents per share on February 26

Cellectis SA CLLS Stock Earnings Reports
Q4'24
Est.
$-0.19
Q3'24
Missed
by $0.03
Q2'24
Beat
by $0.01
Q1'24
Beat
by $0.41
Q4'23
Missed
by $0.43
The last earnings report on November 04 showed earnings per share of -23 cents, missing the estimate of -20 cents. With 12.93K shares outstanding, the current market capitalization sits at 168.21M.
A.I. Advisor
published General Information

General Information

a genome engineering company of pre-engineered products for pharmaceutical industry, cell therapies, seed companies, and laboratory researchers

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
8, rue de la Croix Jarry
Phone
+33 181691600
Employees
285
Web
https://www.cellectis.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYWTX61.430.22
+0.36%
Rydex Emerging Markets 2X Strategy A
VWYIX44.97N/A
N/A
Voya Small Cap Growth R
PGTIX21.67-0.06
-0.28%
T. Rowe Price Global Technology I
HADUX75.39-0.32
-0.42%
Horizon Equity Premium Income Advisor
FSCAX33.05-0.50
-1.49%
Nuveen Small Cap Value A

CLLS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CLLS has been closely correlated with CMVLF. These tickers have moved in lockstep 82% of the time. This A.I.-generated data suggests there is a high statistical probability that if CLLS jumps, then CMVLF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLLS
1D Price
Change %
CLLS100%
-1.45%
CMVLF - CLLS
82%
Closely correlated
N/A
ABCZF - CLLS
58%
Loosely correlated
N/A
SLN - CLLS
43%
Loosely correlated
-3.41%
MDGL - CLLS
40%
Loosely correlated
-1.58%
PMVP - CLLS
38%
Loosely correlated
-2.56%
More